Vincerx Pharma plans to cut costs and explore strategic options to advance Phase 1 study of VIP943, a CD123-targeted antibody-drug conjugate. Dr. Hamdy emphasizes commitment and positive results, aiming to maximize value and support VersAptx platform.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing